Skip to content

URGKA

Active
Private limited companyfounded 2024active for 2 yearsLangstraat 20, 2440 Geel, BelgiumKBO/BCE: BE 1013.873.001
Summary

URGKA has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €243,130 and a net result of €162,748. Its solvency ranks better than 80% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 20-09-2024 Normal situation
Activity
Specialist medical practice NACE 86220
Establishment units
2.364.050.841 2440 Geel, since 20-09-2024
2.364.050.940 3900 Pelt, since 20-09-2024
Financial year end
31 December
Peppol
Reachable since 29-08-2025

Board and ownership

Board

Financial position

98 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
€220,893
▲ 103%
Turnover
≈ €410,000
estimated
Profit
€162,748
▲ 88.4%
Equity
€243,130
▲ 202%
Total assets
€279,052
▲ 156%
Filed on 16-07-2026, 15 days before the deadline
Score breakdownlowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 7.16, cash €119,610Equity €243,130 (87.1% of total assets)Figures for financial year 2025 (filed on 16-07-2026)Show the evidence

Checked score

Score 2025
98 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 86% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency 100+1
equity 87.1% of total assets
Liquidity 98+52
short-term debt 12.9% · cash 42.9%
Profitability 100=
return on assets 58.3%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,160 companies, NACE 86, micro)
Last 24 months 10-2025: 0.1% 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.2%▲ +0.1 percentage points vs 06-2026highest value 08-2026: < 0.1%▼ -0.2 percentage points vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026lowest value 11-2026: < 0.1%● unchanged vs 10-2026lowest value
Credit of up to €23,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity is ample, with a current ratio of 7.16 (2.71 in 2024), above the usual 1.5. Short-term debt is 12.9% and cash 42.9% of total assets. 12.9% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 87% on liquidity, 80% on profitability and 95% on growth.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 7.16, cash €119,610
NBB · annual accounts
lowers risk · Equity €243,130 (87.1% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed on 16-07-2026)
NBB · annual accounts
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 years
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-07-2026, 15 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
15 days early
2024
2 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 2 accounts on average 9 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2024.
KBO publications

Key points

  • Positive: Equity rose in 2025from €80,382 to €243,130 ▲ 202% View
  • Positive: Higher net result than 82% of companies in human healthsector median €60,139 · 20,665 companies €162,748 View

Recent changes

  1. · Gazette deed IncorporationStarting capital €2,000 · Appointment: VAN DRIESSCHE Karen Julia Jean (director)
All 5 events

Comparable companies

These companies have the same main activity as URGKA: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €258,000 and €276,000, founded in 2024.

CompanyTotal assetsGross margin
URGKA Geel€279,052€220,893
Dr. MRSM Zoersel€257,587€238,418
Dr. Dries Knaeps Turnhout€259,638€198,125
GNB Radiology Neupré€275,528€220,480
Dr. L. Beddeleem Wingene€275,904€209,573
SP Nazareth-De Pinte€259,137€203,762
Docteur Lilas Al Zein, Anesthésie Réanimation Mont-Saint-Guibert€275,058€233,269
Full comparison

Key facts about URGKA

What is the company number of URGKA?
The company number of URGKA is 1013.873.001. The VAT number is the same number with BE in front: BE 1013.873.001.
Where is URGKA based?
The registered office is at Langstraat 20, 2440 Geel.Company details
What does URGKA do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of URGKA?
The legal form of URGKA is Private limited company (BV).
When was URGKA founded?
URGKA was founded on 20-09-2024.
Is URGKA still active?
Yes, URGKA is an active enterprise in the KBO register.
What is the turnover of URGKA?
The turnover in financial year 2025 is ≈ €410,000. This figure is estimated from the gross margin of €220,893 and 43 comparable companies (NACE 86220). It probably lies between €350,000 and €550,000.Financials
Is URGKA profitable?
In financial year 2025, URGKA made a profit of €162,748.
Where can I find the annual accounts of URGKA?
URGKA filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of URGKA due?
URGKA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.